Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
ID: 346551Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $225K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346551

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-131.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at enhancing research in maternal and pediatric pharmacology. This grant supports translational and clinical research focused on advancing precision medicine for pregnant individuals, lactating persons, and children, as well as understanding drug action mechanisms and developing safer therapeutics for these populations. The initiative is crucial for improving healthcare outcomes for underrepresented groups, with a funding ceiling of $275,000 available over two years. Interested applicants, including various educational and research institutions, must submit their proposals by May 7, 2026, and can find more information at the NIH grants website or contact grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-131-Full-Announcement.html
    PAR-23-131.html
    The Department of Health and Human Services' funding opportunity aims to enhance maternal and pediatric pharmacology through the R21 Exploratory/Developmental Research Grant. It supports research in three main areas: advancing precision medicine for pregnant individuals and children, understanding drug action mechanisms during pregnancy and lactation, and developing safer therapeutics for these populations. The initiative is spearheaded by the National Institutes of Health, with participation from specific institutes focusing on child health, allergy, and drug abuse. Key objectives include creating innovative tools and methodologies for clinical impact, as well as fostering research into pharmacokinetics to develop safer drug applications. The grant is open for applications until May 2026, offering up to $275,000 in direct costs over two years. Eligible applicants include various educational and research institutions, with an emphasis on interdisciplinary collaboration. The announcement highlights the need for adherence to rigorous application instructions and encourages the sharing of research findings to expand scientific knowledge and improve healthcare outcomes for these underrepresented populations.
    Similar Opportunities
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support translational and clinical research that develops novel tools and methodologies to enhance the understanding of drug action mechanisms and improve the safety and effectiveness of therapeutics for these populations. The initiative is crucial for addressing critical gaps in healthcare for vulnerable groups, with a focus on discovering safer medications and utilizing innovative approaches such as machine learning for precision dosing. Interested applicants can find more information and submit proposals by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating individuals, and children. This initiative seeks to support translational and clinical research that develops novel therapeutic tools, enhances understanding of drug mechanisms, and improves medication safety and efficacy for these vulnerable populations. The program emphasizes interdisciplinary collaboration to address unmet therapeutic needs and promote better health outcomes in maternal and pediatric medicine. Applications will be accepted starting January 5, 2025, with a closing date of May 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html.
    Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center through a cooperative agreement. This initiative aims to enhance drug development and regulatory science for maternal and pediatric therapeutics by creating a pharmacology knowledgebase, utilizing real-world clinical data, and fostering innovative clinical trials, while also training the future workforce in this critical area. The total estimated funding for this program is $3,625,000, with one award anticipated, and interested parties can reach out to Lesly-Anne Samedy-Bates at lesly-anne.samedy-bates@nih.gov or by phone at 301-219-7492 for further information. The estimated synopsis post date is November 21, 2025, with a closing date for applications expected by March 2, 2026, and project commencement anticipated on December 1, 2026.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)" aimed at promoting research and development of novel screening methods and therapeutic interventions for conditions identified through newborn screening. This initiative encourages innovative projects that generate preliminary data on both existing and potentially fatal genetic disorders, emphasizing the importance of early detection and intervention. The program is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and governmental bodies, with a total funding ceiling of $275,000 over two years. Interested applicants should note that the submission deadlines begin on January 16, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Maternal Medications and Human Milk Research Center (M2HMRC)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce a funding opportunity for the establishment of the Maternal Medications and Human Milk Research Center (M2HMRC) as part of its Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. This initiative aims to advance research on the impact of maternal medications on human milk composition and neonatal health outcomes by addressing knowledge gaps, integrating real-world evidence, developing innovative safety tools, and disseminating findings to a wide audience. The total estimated funding for this cooperative agreement is $2.5 million, with one award anticipated, and applications are expected to be solicited following the publication of the Notice of Funding Opportunity (NOFO) on November 3, 2025. Interested parties can reach out to Dr. Zhaoxia Ren at zren@mail.nih.gov or by phone at 240-463-5046 for further information.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) to support innovative research projects in the early stages that can lead to significant advancements in biomedical, behavioral, and clinical research. This funding opportunity requires applicants to propose at least one clinical trial and is aimed at addressing critical gaps in knowledge within the scientific missions of participating NIH Institutes and Centers. Eligible applicants include a diverse range of organizations, such as higher education institutions, nonprofits, and foreign entities, with a total project period limited to two years and a budget of up to $275,000. The application period opens on January 16, 2025, and closes on January 8, 2028; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity (PAR-23-037) aimed at promoting multisite clinical trials and observational studies focused on women, children, pregnant and lactating individuals, and persons with disabilities. The initiative seeks to enhance the rigor and reproducibility of clinical trial protocols, facilitate data sharing, and increase the involvement of diverse populations in research through the utilization of NICHD-supported Network infrastructure. This funding opportunity supports projects for up to five years, with budgets reflecting actual needs, and requires a rigorous pre-application process starting with a Letter of Inquiry. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with ongoing application cycles and a close date set for May 7, 2026.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities" through a cooperative agreement mechanism. This initiative aims to utilize NICHD clinical research network infrastructure to support multisite, investigator-initiated clinical trials and observational studies, focusing on improving health outcomes for vulnerable populations. The funding opportunity emphasizes the importance of diverse participant enrollment and collaboration, requiring applicants to develop a Plan for Enhancing Diverse Perspectives and a Data Management and Sharing Plan. The maximum funding amount is $6,250,000, with a project period of up to seven years, and applications are due by November 15, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-25-311.html.